Revolo Biotherapeutics to Present at the 8th Food Allergy Fund Summit
NEW ORLEANS and CAMBRIDGE, England, April 13, 2023 (GLOBE NEWSWIRE) — Revolo Biotherapeutics (“Revolo Bio”…
News
Jasper Therapeutics Announces Appointment of Matthew Ford as Vice President, Human Resources
REDWOOD CITY, Calif., April 13, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper),…
Jasper Therapeutics Announces Appointment of Matthew Ford as Vice President, Human Resources
REDWOOD CITY, Calif., April 13, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper),…
Intercept to Announce First Quarter 2023 Financial Results and Provide Update on Commercial Launch Strategy for NASH on April 27, 2023
MORRISTOWN, N.J., April 13, 2023 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company…
Intercept to Announce First Quarter 2023 Financial Results and Provide Update on Commercial Launch Strategy for NASH on April 27, 2023
MORRISTOWN, N.J., April 13, 2023 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company…
4DMT to Present Interim Data from 4D-150 Phase 1/2 PRISM Clinical Trial for Wet AMD at ARVO 2023, and Promotes Robert Kim, M.D. to Chief Medical Officer
Interim data to be presented in an oral presentation by Dr. Arshad M. Khanani, M.D.,…
4DMT to Present Interim Data from 4D-150 Phase 1/2 PRISM Clinical Trial for Wet AMD at ARVO 2023, and Promotes Robert Kim, M.D. to Chief Medical Officer
Interim data to be presented in an oral presentation by Dr. Arshad M. Khanani, M.D.,…
Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
– Interim blinded safety and pharmacokinetic data to be presented at the 33rd European Congress…
Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
– Interim blinded safety and pharmacokinetic data to be presented at the 33rd European Congress…
Atreca to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
SAN CARLOS, Calif., April 13, 2023 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a…
Atreca to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
SAN CARLOS, Calif., April 13, 2023 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a…
Mereo BioPharma to Participate in Fireside Chat at the 22nd Annual Needham Healthcare Conference
LONDON, April 13, 2023 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or…
Mereo BioPharma to Participate in Fireside Chat at the 22nd Annual Needham Healthcare Conference
LONDON, April 13, 2023 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or…
Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference
BOSTON, April 13, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company…
Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference
BOSTON, April 13, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company…
Novo Nordisk raises sales and operating profit outlook for 2023
Bagsværd, Denmark, 13 April 2023 – Novo Nordisk today announced the sales and operating profit…
Novo Nordisk raises sales and operating profit outlook for 2023
Bagsværd, Denmark, 13 April 2023 – Novo Nordisk today announced the sales and operating profit…
HCW Biologics Poster Presentation at AACR Annual Meeting 2023
Presentation of data for the mechanism underlying HCW9218 against solid tumors HCW9218 is the clinical-stage,…
HCW Biologics Poster Presentation at AACR Annual Meeting 2023
Presentation of data for the mechanism underlying HCW9218 against solid tumors HCW9218 is the clinical-stage,…
Tonix Pharmaceuticals Expedites Fibromyalgia and Chronic Migraine Programs
Streamlining Phase 3 Fibromyalgia and Phase 2 Chronic Migraine Trials by Eliminating Interim Analyses Topline…